Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Inventory (2023 - 2025)

Tg Therapeutics has reported Change in Inventory over the past 3 years, most recently at -$563000.0 for Q4 2025.

  • Quarterly results put Change in Inventory at -$563000.0 for Q4 2025, down 102.27% from a year ago — trailing twelve months through Dec 2025 was $33.5 million (down 49.96% YoY), and the annual figure for FY2025 was $33.5 million, down 49.96%.
  • Change in Inventory for Q4 2025 was -$563000.0 at Tg Therapeutics, up from -$8.7 million in the prior quarter.
  • Over the last five years, Change in Inventory for TGTX hit a ceiling of $46.3 million in Q1 2025 and a floor of -$8.7 million in Q3 2025.
  • Median Change in Inventory over the past 3 years was $2.6 million (2024), compared with a mean of $11.4 million.
  • Biggest five-year swings in Change in Inventory: skyrocketed 350.78% in 2024 and later tumbled 442.32% in 2025.
  • Tg Therapeutics' Change in Inventory stood at $5.5 million in 2023, then skyrocketed by 350.78% to $24.8 million in 2024, then tumbled by 102.27% to -$563000.0 in 2025.
  • The last three reported values for Change in Inventory were -$563000.0 (Q4 2025), -$8.7 million (Q3 2025), and -$3.6 million (Q2 2025) per Business Quant data.